Disc Medicine

Yahoo Finance • last month

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffe... Full story

Yahoo Finance • last month

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher (CNPV), a program des... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks rose late Friday afternoon with the NYSE Health Care Index climbing 0.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • last month

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering fro... Full story

Yahoo Finance • last month

Achieve, Disc, Revolution among winners of initial FDA national priority vouchers

[US Food and Drug Administration (FDA)] Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]), Disc Medicine (NASDAQ:IRON [https://seekingalpha.com/symbol/IRON]), and Revolution Medicines (NASDAQ:RVMD [https://seeking... Full story

Yahoo Finance • last month

Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPPThe CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) --... Full story

Yahoo Finance • 2 months ago

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc... Full story

Yahoo Finance • 3 months ago

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equival... Full story

Yahoo Finance • 3 months ago

Cantor Fitzgerald reiterates Overweight rating on Disc Medicine stock

Investing.com - Cantor Fitzgerald maintained its Overweight rating and $132.00 price target on Disc Medicine (NASDAQ:IRON) on Wednesday. The company, currently trading at $58.18 with a market capitalization of $2 billion, has seen its stoc... Full story

Yahoo Finance • 3 months ago

Bitterman Kevin, director at Disc Medicine, sells $1.96m in iron stock

Director Kevin Bitterman of Disc Medicine, Inc. (NASDAQ:IRON) sold a total of 32,174 shares of common stock on August 13 and 14, 2025. The sales, executed under a prearranged Rule 10b5-1 trading plan, totaled $1.96 million. The biotech com... Full story

Yahoo Finance • 4 months ago

Disc medicine CFO Franchi sells $119k in shares

Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (NASDAQ:IRON), sold 2,031 shares of common stock on July 17, 2025, at a price of $59.00, totaling $119,829. The transaction occurred near the stock’s current trading price of... Full story

Yahoo Finance • 5 months ago

Commodity Roundup: Gold rises as tariff worries lift safe-haven demand ahead of key inflation data

[gold bars on brown background] Sanlad/iStock via Getty Images Gold prices (XAUUSD:CUR [https://seekingalpha.com/symbol/XAUUSD:CUR]) edged higher on Tuesday as concerns over the impact of US tariffs boosted the metal’s safe-haven appeal,... Full story

Yahoo Finance • 5 months ago

Disc Medicine CEO Quisel sells $286k in shares

Disc Medicine, Inc. (NASDAQ:IRON) Chief Executive Officer John D Quisel, sold 5,200 shares of common stock on July 3, 2025, at prices ranging from $55.00 to $55.26, for a total value of $286,454. The transaction occurred with the stock tra... Full story

Yahoo Finance • 5 months ago

Vietnam slaps anti-dumping tariffs on hot-rolled steel imports from China

[Iron pipe centrifugal pipe casting machine at the foundry] Vladimir Zapletin/iStock via Getty Images Vietnam’s Ministry of Industry and Trade has imposed five-year anti-dumping duties on certain hot-rolled steel imports from China, effec... Full story

Yahoo Finance • 5 months ago

H.C. Wainwright reaffirms Buy rating on Disc Medicine stock at $118 target

Investing.com - H.C. Wainwright has reiterated its Buy rating and $118.00 price target on Disc Medicine (NASDAQ:IRON), maintaining its positive outlook on the biopharmaceutical company. Currently trading at $53.17, the stock has shown stro... Full story

Yahoo Finance • 6 months ago

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-09... Full story

Yahoo Finance • 6 months ago

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from... Full story

Yahoo Finance • 9 months ago

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive update from Phase 1b trial of... Full story

Yahoo Finance • 10 months ago

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffe... Full story

Yahoo Finance • 10 months ago

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffe... Full story